Today, we chronicle two more decisions from the Zantac MDL. Once again, kudos to this MDL transferee judge for outstanding willingness to tackle legal issues, and decide them, at an early stage of the litigation. Because we’ve gone through these issues before, here and here, we discuss these latest rulings in one post.
Chronicle
Still more Zantac MDL dismissal orders.
Today’s installment grants dismissal of the plaintiffs’ medical monitoring claims, and also sheds some light on the questionable factual basis of everything being asserted in this MDL. As we’ve pointed out in our prior posts (such as this one), plaintiffs allege that the active ingredient in this drug
Lots of cases get parked in MDLs. There is no denying it. It’s built into the system. Individual cases get brought together in a single court for the purpose of consolidated pretrial proceedings. For the most part, except for cases selected as bellwethers, that means MDLs are focused on general discovery, general experts, and general
There is a lot of scholarship and other material out there on issues having to do with federal multidistrict litigation (“MDL”) practice. See, e.g., footnote three, in the article below. But state MDL equivalents? Not so much. The Blog’s co-founder wrote a book about this a while ago, see Herrmann, et al.,
This post is from the non-Reed Smith side of the blog.
This blog has repeatedly lamented the tendency of MDL courts to flout federal pleading standards when assessing the sufficiency of master complaints. All too often MDL courts disregard Rule 8(a), which—as authoritatively interpreted by the Supreme Court in Twombly and Iqbal—requires plaintiffs to
We have long endorsed the use of Lone Pine orders as a partial antidote to wasteful mass litigation. The issue is the numbers, large numbers of meritless claims that are parked in a mass proceeding, such as an MDL, where they both strain judicial resources and detract from litigation of claims that have arguable merit.
Today’s guest post is by the Reed Smith team of Shana E. Russo, Jennifer A. Eppensteiner, and Kathy I. Oviedo. It is about multi-district litigation (“MDL”) practice, and specifically, compares and contrasts various ways of selecting plaintiffs for possible bellwether trials. It also useful in providing links to orders entered in a
By now our beef with Multidistrict Litigations has become monotonous: plaintiff lawyers assemble enormous inventories of weak cases, then contort the bellwether pool to ensure that only their best cases go to trial. We remember an oral argument in front of an MDL judge in which we employed statistics to show that a representative MDL
We’ve complained before about MDL “master” or “consolidated” complaints being used to deprive defendants of the ability to pursue their rights to seek dismissal on TwIqbal and other pleading-related grounds. In individual actions, defendants have the right to put the plaintiffs’ pleadings to the test required by Rules 8 and 12. That has not necessarily
Late last year we awarded our #10 spot on our Worst of 2020 post to In re Valsartan, Losartan, & Irbesartan Products Liability Litigation, 2020 WL 7418006 (D.N.J. Dec. 18, 2020) (“VLI”). At that point the decision was brand new, and we promised a more in-depth analysis. Here it is.
VLI fits